Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Leases (2019 - 2026)

Intellia Therapeutics has reported Current Leases over the past 8 years, most recently at $19.1 million for Q1 2026.

  • Quarterly Current Leases fell 50.74% to $19.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.1 million through Mar 2026, down 50.74% year-over-year, with the annual reading at $26.5 million for FY2025, 30.79% up from the prior year.
  • Current Leases was $19.1 million for Q1 2026 at Intellia Therapeutics, down from $26.5 million in the prior quarter.
  • Over five years, Current Leases peaked at $38.8 million in Q1 2025 and troughed at $9.3 million in Q1 2022.
  • The 5-year median for Current Leases is $18.8 million (2024), against an average of $19.6 million.
  • Year-over-year, Current Leases surged 106.59% in 2025 and then plummeted 50.74% in 2026.
  • A 5-year view of Current Leases shows it stood at $16.7 million in 2022, then rose by 11.47% to $18.6 million in 2023, then increased by 8.86% to $20.2 million in 2024, then soared by 30.79% to $26.5 million in 2025, then decreased by 27.89% to $19.1 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Current Leases are $19.1 million (Q1 2026), $26.5 million (Q4 2025), and $27.4 million (Q3 2025).